Smoking Cessation – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Smoking Cessation – Drugs In Development, 2024 report and make more profitable business decisions.
Smoking is addictive; smokers experience an uncontrollable dependence on cigarettes, and stopping can cause severe mental, emotional, or physical reactions. People addicted to smoking develop a tolerance to nicotine. Nicotine acts on acetylcholine receptors, causing the body to react to nicotine at these receptors in the same manner as it responds to acetylcholine. This leads to alterations in the activity and physiological functions of many brain systems. This causes structural and functional changes in the brains of smokers. Upon sudden nicotine withdrawal, the brain and other parts of the body are disturbed, leading to a condition called withdrawal syndrome. The body usually takes time to function in the absence of nicotine. Symptoms include anger, depression, weight gain, headaches, and dizziness. The effects of smoking withdrawal stem from the lack of nicotine that can be overcome by nicotine replacement therapies such as the use of nicotine patches or nicotine chewing gum.
The Smoking Cessation drugs in development market research report provide comprehensive information on the therapeutics under development for Smoking Cessation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Smoking Cessation and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Smoking Cessation | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 46 molecules, with 41 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Smoking Cessation therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Smoking Cessation pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Smoking Cessation treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Achieve Life Sciences IncAmygdala Neurosciences Inc
Antidote Therapeutics Inc
Astraea Therapeutics LLC
Avicanna Inc
Axsome Therapeutics Inc
Boryung Pharmaceutical Co Ltd
Camino Pharma LLC
Ceruvia Lifesciences LLC
Cessation Therapeutics Inc
Chronos Therapeutics Ltd
Clairvoyant Therapeutics Inc
Currax Pharmaceuticals LLC
CV Sciences Inc
DemeRx Inc
Embera NeuroTherapeutics Inc
EncepHeal Therapeutics Inc
Entheon Biomedical Corp
Eolas Therapeutics Inc
EpiVario Inc
Ethismos Research Inc
Incannex Healthcare Ltd
Italian Institute of Technology
Kenox Pharmaceuticals Inc
MAKScientific LLC
Miist Therapeutics Inc
Molecular Express Inc
Mydecine Innovations Group Inc
NAL Pharmaceuticals Ltd
National Institute on Drug Abuse
NFL Biosciences SA
Novo Nordisk AS
Omeros Corp
Ophidion Inc
Palisades Therapeutics
Qnovia Inc
Sunomix Therapeutics
The Scripps Research Institute
Virginia Polytechnic Institute and State University
Wake Forest University
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Smoking Cessation reports